Cytosorbents Price to Free Cash Flow Ratio 2010-2025 | CTSO

Cytosorbents price to free cash flow ratio from 2010 to 2025. Price to free cash flow ratio can be defined as

Cytosorbents Price to Free Cash Flow Ratio 2010-2025 | CTSO

Cytosorbents price to free cash flow ratio from 2010 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$223.7B
Boston Scientific (BSX)$157.9B
Stryker (SYK)$152.8B
EssilorLuxottica (ESLOY)$137.4B
Medtronic (MDT)$117.5B
Lonza Group Ag (LZAGY)$49.5B
Haleon (HLN)$43.3B
ResMed (RMD)$40.7B
Agilent Technologies (A)$33.5B
GE HealthCare Technologies (GEHC)$32.8B
Koninklijke Philips (PHG)$25.8B
Terumo (TRUMY)$25.1B
Insulet (PODD)$21B
Zimmer Biomet Holdings (ZBH)$18.5B
Baxter (BAX)$14.4B
Smith & Nephew SNATS (SNN)$13.5B
Sunny Optical Technology (SNPTF)$10.4B
Demant (WILYY)$8.6B
Bio-Rad Laboratories (BIO)$6.8B
Lantheus Holdings (LNTH)$5B
Perrigo (PRGO)$3.8B
Prestige Consumer Healthcare (PBH)$3.7B
Haemonetics (HAE)$3.6B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Envista Holdings (NVST)$3.4B
ICU Medical (ICUI)$3.1B
LeMaitre Vascular (LMAT)$1.9B
AtriCure (ATRC)$1.7B
QuidelOrtho (QDEL)$1.6B
Acuren (TIC)$1.4B